Global medical aesthetics company Classis Co., Ltd. (CEO Choi Yoon-seok) announced on the 15th that it has received attention from global investors as a 'stock to watch this year' after concluding a panel discussion held at the '2026 JP Morgan Healthcare Conference (JPMHC),' the world's largest pharmaceutical and bio investment event.
On the 14th (local time), Classys participated in the conference's official program panel session and led a discussion on the topic of "Beyond K-Beauty." This session marked an unusual case for the JP Morgan Healthcare Conference to feature K-Beauty as a key topic, and the discussion focused on the global aesthetics and medical industry, led by Korean companies, and on investor interest. Classys was the only global EBD equipment company invited and the first Korean company to lead the panel discussion.
During the discussion, Classis presented the future direction of K-beauty medicine, the competitiveness of EBD technology, and its mid- to long-term growth strategy. The company shared its portfolio of aesthetic EBD devices, including Shrink Universe (HIFU), Volnumer (Monopolar RF), and Quadsay (Microneedle RF), as well as its global market expansion strategy through the home beauty device "Lift2Glow," launched this year.
Dr. Mark Halsey, a dermatologist who participated in the panel, praised the Classis device for its high patient satisfaction and superior treatment efficiency, explaining that it will establish itself as a differentiated solution in the US market. An American investor also offered a positive assessment, citing the acquisition of a Brazilian subsidiary and the establishment of a direct distribution system, which will allow the device to expand its global market share.
This panel discussion provided investors with an opportunity to explore the structural growth potential of the K-beauty industry and Classis' recurring revenue-based business model. During the discussion, Classis highlighted its long-term investment appeal by emphasizing its combined treatment protocol and recurring structure, which maximizes customer lock-in.
Kim Rae-hee, head of marketing at Classis, said, “Classis will evolve beyond a cosmetic medical device company into a company that manages the entire customer lifestyle,” and announced plans to continue aggressive business expansion with the goal of achieving $1 billion in sales and an operating profit margin of over 50% in the global market.
Participation in this panel discussion further strengthened Classis' global recognition and investor confidence, and led to positive evaluations of the long-term potential of its K-beauty technology and market expansion strategy.
You must be logged in to post a comment.